|
Anti-B7H3 ADC
|
Oncology/Cancer
|
Broad cancer
|
PCC
|
Global
| |
|
Best-in-class IRAK4 degrader
|
Immunological disease
|
Psoriasis,RA,IBD
|
PCC
|
Global
| |
|
NF-κB inhibitor
|
Oncology/Cancer
|
Cancer cachexia
|
PCC
|
Global
| |
|
See in our "Antibody Licensing" platform
|
|
Next to "Licensing" Tab in the top
|
PCC
|
| |
|
ActRIIB inhibitor
|
Oncology/Cancer
|
Cancer cachexia
|
Preclinical
|
Global
| |
|
B7H3/PD-L1 bsAb
|
Oncology/Cancer
|
Advanced solid tumor
|
Preclinical
|
Global
| |
|
BCL-XL PROTAC
|
Oncology/Cancer,Ophthalmology disease
|
small cell lung cancer,non-small cell lung cancer,lymphoma,acute myeloid leukemia,acute lymphocytic leukemia,diabetic macular edema,diabetic retinopathy
|
Preclinical
|
Global
| |
|
CCR8 mAb (sequence cooperation)
|
Oncology/Cancer
|
Solid Tumor
|
Preclinical
|
Global
| |
|
FRa BsAb (sequence cooperation)
|
Oncology/Cancer
|
Ovarian cancer
|
Preclinical
|
Global
| |
|
GCC mAb (sequence cooperation)
|
Oncology/Cancer
|
Solid Tumor
|
Preclinical
|
Global
| |
|
GLP-1/GIP/FGF21 fusion protein
|
Metabolic disease
|
NASH,Type 2 diabetes,hyperlipidemia
|
Preclinical
|
Global (except China)
| |
|
GPCR selective agonist
|
Immunological disease
|
Duchenne muscular dystrophy,SLE
|
Preclinical
|
Global
| |
|
B7H3+CD3 BsAb
|
Oncology/Cancer
|
Solid Tumor
|
IND
|
Global
| |
|
CD47 mAb
|
Oncology/Cancer
|
Advanced solid tumor,Advanced hematological tumor
|
IND
|
Global
| |
|
CLDN 18.2 CAR-T
|
Oncology/Cancer
|
Gastric Cancer,Pancreatic Cancer
|
IND
|
Global
| |
